The Lipotoxicity and Glucotoxicity Hypothesis in the Metabolic Syndrome and Type 2 Diabetes

The Metabolic Syndrome at the Beginning of the XXI Century: A Genetic and Molecular Approach

Volumn , Issue , 2005, Pages 271-282

  Dimitriadis, George ^a   Boutati, Eleni ^a   Raptis, Sotirios A ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic National Centre for Research Prevention and Treatment of Diabetes ^*  (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879552855     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-84-8174-892-5.50016-4     Document Type: Chapter

References (102)

1. Kahn S The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 46:3-19.
2. Dostou J, Gerich J Pathogenesis of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001, 109(Suppl 2):149-156.
3. Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag A Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes 2005, 54(1):275-283. Jan.
4. Heine R, Dekker J Beyond postprandial hyperglycemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002, 45:461-475.
5. Castro-Cabezas M, Erkelens W Triglycerides and atherosclerosis: to feast or fast. The Netherlands J Med 2000, 56:110-118.
6. Henry R Preventing cardiovascular complications of type 2 diabetes: focus on lipid management. Clin Diabetes 2001, 19:113-120.
7. Gavrilova O, Marcus-Samuels B, Graham D, Kim J, Shulman G, Castle A, Vinson C, Eckhaus M, Reitman M Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000, 105:271-278.
8. Ahima R, Flier J Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000, 11:327-332.
9. Coppack S, Patel J, Lawrence V Nutritional regulation of lipid metabolism in human adipose tissue. Exp Clin Endocrinol Diabetes 2001, 109(Suppl 2):202-214.
10. Frayn K Adipose tissue as a buffer for daily lipid flux. Diabetologia 2002, 45:1201-1210.
11. Jensen M Adipose tissue and fatty acid metabolism in humans. J R Soc Med 2002, 95(Suppl 42):3-7.
12. Frayn K, Shahid S, Hamlani R, Humphreys S, Clark M, Fielding B, Boland O, Coppack S Regulation of fatty acid movement in human adipose tissue in the postabsorptive to postprandial transition. Am J Physiol 1994, 266:E308-E317.
13. Randle P, Garland P, Hales C, Newsholme E The glucose-fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
14. Newsholme E, Dimitriadis G Integration of biochemical and physiological effects of insulin on glucose metabolism. Exp Clin Endocrinol Diabetes 2001, (Suppl 2):122-134.
15. Groop L, Bonadonna R, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo R Glucose and free fatty acid metabolism in NIDDM. J Clin Invest 1989, 84:205-213.
16. Kim J, Wi J, Youn J Plasma free fatty acids decrease insulin-stimulated skeletal muscle glucose uptake by suppressing glycolysis in conscious rats. Diabetes 1996, 45:446-453.
17. Shulman G Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
18. Boden G Effects of free fatty acids on glucose metabolism: Significance for insulin resistance and type 2 diabetes. Horm Metabol Res 2003, 111:121-124.
19. Shah P, Vella A, Basu A, Basu R, Adkins A, Schwenk W, Johnson C, Nair KS, Jensen M, Rizza RA Elevated fatty acids impair glucose metabolism in women. Diabetes 2003, 52:38-42.
20. Randle P Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998, 14:263-283.
21. Ruderman N, Saha A, Vamvas D, Witters L Malonyl-CoA, fuel sensing and insulin resistance. Am J Physiol 1999, 276:E1-E18.
22. Duan G, Winder W Control of malonyl-CoA by glucose and insulin in perfused skeletal muscle. J Appl Physiol 1993, 74:2543-2547.
23. Jensen M Fatty acid oxidation in human skeletal muscle. J Clin Invest 2002, 110:1607-1609.
24. Kraegen W, Cooney G, Ye A, Thompson S, Furler S The role of lipids in the pathogenesis of muscle insulin resistance and beta-cell failure in type 2 diabetes and obesity. Exp Clin Endocrinol Diabetes 2001, 109(Suppl 2):189-201.
25. Unger R Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes 1995, 44:863-870.
26. Miles J, Wooldridge D, Grellner W, Windsor S, Isley W, Klein S, Harris W Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic patients. Diabetes 2003, 52:675-681.
27. Dimitriadis G, Boutati E, Lambadiari V, Mitrou P, Maratou E, Brunel P, Raptis S Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism. Eur J Clin Invest 2004, 34:490-497.
28. Newsholme E, Bevan S, Dimitriadis G, Kelly R Physiological aspects of insulin action. Insulin: Molecular Biology to Pathology 1992, 155-190. IRL Press Oxford, New York, Toronto, Chapter 5. F. Ashcroft, S. Ashcroft (Eds.).
29. Kelley D, Goodpaster B Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance. Diabetes Care 2001, 24:933-941.
30. Philips D, Caddy S, Ilic V, Fielding B, Frayn K, Borthwick A, Taylor R Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 1996, 45:947-950.
31. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L Intramyocellular triglyceride content is a determinant of in-vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic patients. Diabetes 1999, 48:1600-1606.
32. Schaffer J Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003, 14:281-287.
33. Wititsuwannakul D, Kim K Mechanism of palmityl coenzyme Ainhibition of liver glycogen synthase. J Biol Chem 1977, 252:7812-7817.
34. Carling D, Zammit V, Hardie D A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett 1987, 223:217-222.
35. Schmitz-Peiffer C, Browne C, Oakes N, Watkinson A, Chisholm D, Kraegen E, Biden T Alterations in the expression and cellular localization of protein kinase-C isoenzymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 1997, 46:169-178.
36. Griffin M, Marcucci M, Cline G, Bell K, Barucci N, Lee D, Goodyear L, Kraegen E, White M, Shulman G Free fatty acid-induced insulin resistance is associated with activation of protein kinase-C theta and alterations in the insulin signaling cascade. Diabetes 1999, 48:1270-1274.
37. Itani S, Ruderman N, Schmieder F, Boden G Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol protein kinase-C and IκBβ. Diabetes 2002, 51:2005-2011.
38. Yu C, Chen Y, Cline G, Zhang D, Zong H, Wang Y, Bergeron R, Kim J, Cushman S, Cooney G, Atcheson B, White M, Kraegen E, Shulman G Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phopsphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002, 277:50230-50236.
39. Lemberger T, Desvergne B, Wahli W Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Ann Rev Cell Dev Biol 1996, 12:335-363.
40. Spiegelman B PPARγ - Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514.
41. Turinsky J, O' Sullivan D, Bayly B AT1,2-diacylglycerol and ceramides levels in insulin-resistant tissues of the rat invivo. J Biol Chem 1990, 265:16880-16885.
42. Schmitz-Peiffer C, Craig D, Biden T Ceramide generation issufficient to account for the inhibition of the insulinstimulated PKB pathway in C2C12 skeletal muscle cells pre-treated with palmitate. J Biol Chem 1999, 274:24202-24210.
43. Summers S, Garza L, Zhou H, Birnbaum M Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramides. Mol Cell Biol 1998, 18:5457-5464.
44. Storlien L, Kriketos A, Calvert G, Baur L, Jenkins A Fatty acids, triglycerides and syndromes of insulin resistance. Prostagland Leuk Essent Fatty Acids 1997, 57:379-385.
45. Oakes N, Bell K, Furler S, Camilleri S, Saha A, Ruderman N, Chisholm D, Kraegen E Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise - parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acid acyl-CoA. Diabetes 1997, 46:2022-2028.
46. Baynes J Role of oxidative stress in development of complications of diabetes. Diabetes 1991, 40:405-412.
47. Lebovitz H Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001, 109(Suppl 2):135-148.
48. Abate N, Garg A, Peshock R, Stray-Gundersen J, Grundy S Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995, 96:88-98.
49. Carey D, Jenkins A, Campbell L, Freund J, Chisholm D Abdominal fat and insulin resistance in normal and overweight women - direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996, 45:633-638.
50. Barzilai N, She L, Liu B, Viguin P, Cohen P, Wang J, Rossetti L Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999, 48:94-98.
51. Goodpaster B, Kelley D, Wing R, Meier A, Thaete F Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999, 48:839-847.
52. Kelley D, Goodpaster B, Wing R, Simoneau J Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity and weight loss. Am J Physiol 1999, 277:E1130-E1141.
53. Kelley D, Mandarino L Fuel selection in human skeletal muscle in insulin resistance. Diabetes 2000, 49:677-683.
54. Marceau P, Biron S, Hould F, Marceau S, Simard S, Thung S, Kral J Liver pathology and the metabolic syndrome in severe obesity. J Clin Endocrinol 1999, 84:1513-1517.
55. Clain D, Lefkowitch J Fatty liver disease in morbid obesity. Gastroenterol Clin North Am 1987, 16:239-252.
56. Andersen T, Gluud C Liver morphology in morbid obesity: a literature study. Int J Obesity 1984, 8:97-106.
57. Marchesini G, Brizi M, Morselli-Labate A, Bianchi G, Bugianesi E, McCullough A, Forlani G, Melchionda N Association of non-alcoholic fatty-liver disease with insulin resistance. Am J Med 1999, 107:450-455.
58. Saloranta C, Koivisto V, Widen E, Falholt K, DeFronzo R, Harkonen M, Groop L Contribution of liver and muscle to glucose-fatty acid cycle in humans. Am J Physiol 1993, 264:E599-E605.
59. Shah P, Basu A, Rizza R Fat-induced liver insulin resistance. Curr Diab Rep 2003, 3:214-218.
60. Ryysy L, Hakkinen A, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000, 49:749-758.
61. Unger R, Yan-Ting Zhou Lipotoxicity of β-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001, 50(Suppl 1):118-121.
62. Crespin S, Greenough W, Steinberg D Stimulation of insulin secretion by long-chain free fatty acids: a direct pancreatic effect. J Clin Invest 1973, 52:1979-1984.
63. Chalkley S, Kraegen E, Furler S, Campbell L, Chisholm D Non-esterified fatty acid elevation during a hyperglycemic clamp enhances insulin secretion. Diabetic Medicine 1998, 15:327-333.
64. Shafrir E, Raz I Diabetes mellitus or lipidus?. Diabetologia 2003, 46:433-440.
65. McGarry J, Dobbins R Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999, 42:128-138.
66. Zhou Y, Grill V Long-term exposure to fatty acids and ketones inhibits β-cell function in human pancreatic islets of langerhans. J Clin Endocrinol Metab 1995, 80:1584-1590.
67. Shimabukuro M, Zhou Y, Levi M, Unger R Fatty acid induced β-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998, 95:2498-2502.
68. Rossetti L Glucose toxicity: effect of chronic hyperglycemia on insulin action. Diabetes mellitus: a fundamental and clinical text 2004, 939-951. Lippincott Williams & Wilkins, Philadelphia, London. 3 rd Edition. D. LeRoith, S. Taylor, J. Olefsky (Eds.).
69. Yki-Jarvinen H Glucose toxicity. Endocr Rev 1992 Aug, 13(3):415-431. Review. No abstract available.
70. Yki-Jarvinen H, Helve E, Koivisto VA Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes 1987 Aug, 36(8):892-896.
71. Vuorinen-Markkola H, Koivisto VA, Yki-Jarvinen H Mechanisms of hyperglycemia-induced insulin resistance in whole body and skeletal muscle of type I diabetic patients. Diabetes 1992 May, 41(5):571-580.
72. Beck-Nielsen H, Richelsen B, Hasling C, Nielsen OH, Heding L, Sorensen NS Improved in vivo insulin effect during continuous subcutaneous insulin infusion in patients with IDDM. Diabetes 1984, 33(9):832-837. Sep.
73. Yki-Jarvinen H, Koivisto V Natural history of insulin resistance in type 1 diabetes. N Engl J Med 1986, 315:224-230.
74. Kosaka K, Kuzuya T, Akanuma Y, Hagura R Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980, 18:23-28.
75. Garvey T, Olefsky J, Griffin J, Hamman R, Kolterman O The effects of insulin treatment on insulin secretion and insulin action in type 2 diabetes mellitus. Diabetes 1985, 34:222-234.
76. Garvey T, Huecksteadt T, Matthaei S, Olefsky J Role of glucose transporters in the cellular insulin resistance of type 2 non-insulin dependent diabetes mellitus. J Clin Invest 1988, 81:1528-1536.
77. Garvey T, Olefsky J, Matthaei S, Marshall S Glucose and insulin co-regulate the glucose transporter system in primary cultured adipocytes: a new mechanism of insulin resistance. J Biol Chem 1987, 262:189-197.
78. Van Putten J, Krans H Glucose as a regulator of insulinsensitive hexose uptake in 3T3 adipocytes. J Biol Chem 1985, 260:7996-8001.
79. Sasson S, Cerasi E Substrate regulation of the glucose transport system in rat skeletal muscle. J Biol Chem 1986, 261:16827-16833.
80. Kletzien R, Perdue J Induction of sugar transport in chick embryo fibroblasts by hexose starvation: evidence for transcriptional regulation of transport. J Biol Chem 1975, 250:593-600.
81. Rossetti L, Smith D, Shulman G, Papachristou D, DeFronzo R Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987, 79:1510-1515.
82. Kahn B, Shulman G, DeFronzo R, Cushman S, Rossetti L Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin resistant glucose transport in adipocytes without restoring glucose transporter gene expression. J Clin Invest 1991, 87:561-570.
83. Dimitrakoudis D, Ramlal T, Rastogi S, Vranic M, Klip A Glycemia regulates the glucose transporter number in the plasma membrane of the rat skeletal muscle. Biochem J 1992, 284:341-348.
84. Sreekumar R, Halvatsiotis P, Coenen Schimke J, Nair S Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 2002, 51:1913-1920.
85. Robertson P, Harmon J, Tanaka Y, Onah Tran P, Poitut V Glucose toxicity of the β-cell: Cellular and molecular mechanisms. Diabetes mellitus: a fundamental and clinical text 2004, p129-139. Lippincott Williams & Wilkins, Philadelphia, London. 3 rd edition. D. LeRoith, S. Taylor, J. Olefsky (Eds.).
86. Gerich J, Charles M, Grodsky G Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. J Clin Invest 1974, 54:833-841.
87. Kipnis D Insulin secretion in diabetes mellitus. Ann Int Med 1969, 69:891-901.
88. Gerich J, Langlois M, Noacco D, Karam J, Forsham P. Lack of glucagons response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic α-cell defect. Science 173;182:171-173.
89. Leahy J Detrimental effects of chronic hyperglycemia on the pancreatic β-cell. Diabetes mellitus: a fundamental and clinical text 2004, 115-127. Lippincott Williams & Wilkins, Philadelphia, London. 3 rd edition. D. LeRoith, S. Taylor, J. Olefsky (Eds.).
90. Dimitriadis G, Pehling G, Gerich J Abnormal glucose modulation of islet A- and B-cell responses to arginine in non-insulin dependent diabetes mellitus. Diabetes 1985, 34:541-547.
91. Briand J, Rouault C, Reach G, Poitout V Long-term exposure of isolated rat islets to supraphysiologic glucose concentrations decreases insulin mRNA levels. Metabolism 1999, 48:319-323.
92. Moran A, Zhang H, Olson L, Harmon T, Poitout V, Robertson R Differentiation of glucose toxicity from β-cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line HIT-T15. J Clin Invest 1997, 99:534-539.
93. Harmon J, Gleason C, Tanaka Y, Poitout V, Roberston R Antecedent hyperglycemia, not hyperlipidemia is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 2001, 50:2481-2486.
94. Poitout V, Robertson R Secondary β-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143:339-342.
95. Dimitriadis G, Cryer Ph, Gerich J Prolonged hyperglycemia during infusion of glucose and somatostatin impairs pancreatic A- and B-cell responses to decrements in plasma glucose in normal man: evidence for induction of altered sensitivity to glucose. Diabetologia 1985, 28:63-69.
96. Giardino I, Fard A, Hatchell D, Brownlee M Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation and oxidant-induced apoptosis. Diabetes 1998, 47:1114-1120.
97. Scmeltz R, Wendorf H, Field J Effect of control of blood glucose on plasma insulin responses to various stimuli in secondary failures to oral hypoglycemic agents and in newly diagnosed maturity onset, ketosis-resistant diabetics. J Clin Endocrinol Metab 1978, 46:519-527.
98. Savage P, Bennion L, Flock E, Nagulesparan M, Mott D, Roth J, Unger R, Bennett P Diet-induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus. J Clin Endocrinol Metab 1979, 48:999-1007.
99. Raskin P, Pietri A, Unger R Changes in glucagon levels after four to five weeks of glucoregulation by portable insulin infusion pumps. Diabetes 1979, 28:1033-1035.
100. Berger D, Floyd J, Pek S The effect of treatment of type 2 diabetes mellitus on plasma concentrations of pancreatic polypeptide and glucagon. Diabetologia 1981, 21:120-125.
101. Vague P, Moulin J The defective glucose sensitivity of the β-cell in non-insulin dependent diabetes: improvement after 20 hours of normoglycemia. Metabolism 1982, 31:139-142.
102. Raptis S, Dimitriadis G Oral hypoglycemic agents: insulin secretagogues, α-glucosidase inhibitors and insulin sensitizers. Exp Clin Endocrinol Diabetes 2001, 109(Suppl 2):265-287.